Cardiogenic shock (CGS) affects up to 10% of patients suffering acute coronary syndrome. It has a 30 day mortality of 45-50%. No pharmacological nor intervention/device trials have had any impact on this mortality in the last 20 years.
The EURO SHOCK Trial (supported by the European Union Horizons 2020 programme) will randomise 428 patients with CGS following acute coronary syndrome from 44 EU centres to early intervention with Extra Corporeal Membrane Oxygenation (ECMO) therapy or to standard treatment (with no ECMO). This intervention is a high cost specialist centre procedure that warrants further investigation including economic appraisal. Multiple mechanistic and hypothesis generating sub-studies will be undertaken.
ClinicalTrials.gov ID: NCT03813134
Sponsor
University of Leicester
Primary endpoints
All-cause mortality at 30 days following admission with acute coronary syndrome and cardiogenic shock.
Secondary endpoints include 12-month all-cause mortality, heart failure hospitalization, and their composite, as well as cost-effectiveness and quality of life.
CERC Services
- Monitoring activities
Countries
UK, Germany, Belgium, Spain, Norway, Latvia, Italy, Austria
Number of investigational sites
41
Number of patients
428
